PSD 506

Drug Profile

PSD 506

Alternative Names: PSD-506

Latest Information Update: 28 May 2014

Price : $50

At a glance

  • Originator Roche
  • Developer Plethora Solutions
  • Class Urologics
  • Mechanism of Action Muscarinic M2 receptor antagonists; Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Neurogenic bladder; Overactive bladder

Most Recent Events

  • 25 Feb 2013 Discontinued - Phase-II for Overactive bladder in United Kingdom (PO)
  • 25 Feb 2013 Discontinued - Phase-II for Neurogenic bladder in United Kingdom (PO)
  • 24 Jan 2011 PSD 506 is still available for licensing as of 24 Jan 2011. http://www.plethorasolutions.co.uk
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top